Autologous dendritic cell based adoptive immunotherapy of patients with colorectal cancer - A phase i-ii study

Pathology and Oncology Research

Volumn 20, Issue 2, 2014, Pages 357-365

  Hunyadi, János ^a   András, Csilla ^a   Szabó, Imre ^a   Szántó, János ^a   Szluha, Kornélia ^a   Sipka, Sándor ^a   Kovács, Péter ^a   Kiss, Attila ^a   Szegedi, Gyula ^a   Altorjay, István ^a   Sápy, Péter ^a   Antal Szalmás, Péter ^a   Tóth, László ^a   Fazekas, György ^a   Rajnavölgyi, Éva ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Autologous; Colorectal cancer; Dendritic cell; Vaccination

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; DENDRITIC CELL VACCINE; AUTOANTIGEN; TUMOR ANTIGEN;

ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER IMMUNIZATION; CANCER MORTALITY; CANCER RECURRENCE; CELL LYSATE; CLINICAL ARTICLE; COLORECTAL CANCER; DENDRITIC CELL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE ERYTHEMA; LYMPHOCYTE PROLIFERATION; MALE; MIDDLE AGED; ONCOLYSATE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL NEOPLASMS; IMMUNOLOGY; PHYSIOLOGY; PROCEDURES; TUMOR RECURRENCE;

ADOLESCENT; AGED; ANTIGENS, NEOPLASM; AUTOANTIGENS; CARCINOEMBRYONIC ANTIGEN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 84898782435     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-013-9704-3     Document Type: Article

References (50)

1. Van-den-Eynde BJ, Van-der-Bruggen P (1997) T cell defined tumor antigens. Curr Opin Immunol 9:684-693
2. Salgaller ML, Thurner M, Bartsch G, Boynton AL, Murphy GP (1999) Report from the International Union Agaist Cancer (UICC) Tumor Biology Committee: UICC Workshop on the use of dendritic cells in cancer clinical trials. Cancer 86:2674-2683
3. Sokolof MH, Vogelzang N (1999) The ongoing evolution of dendritic cell therapy. Cancer 86:2593-2596
4. Knuth A, Wölfel T, Klehmann E, Boon T, Büschenfelde KM (1989) Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci U S A 86:2804-2808
5. Davis ID, Jefford M, Parente P, Cebon J (2003) Rational approaches to human cancer immunotherapy. J Leuk Biol 73:3-29
6. Liviu V, Titu E, John R, Monson E, Greenman J (2002) The role of CD8+ T cells in immune responses to colorectal cancer. Cancer Immunol Immunother 51:235-247
7. Rock KL, Gamble S, Rothstein L (1990) Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 249:918-921
8. Tatsumi T, Takehara T, Kanto T, Miyagi T, Kuzushita N, Sugimoto Y, Jinushi M, Kasahara A, Sasaki Y, Hori M, Hayashi N (2001) Adminstration of interleukin 12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res 61:7563-7567
9. Tuting T, Wilson CC, Martin DM, Kasamon YL, Rowles J, Ma DI, Slingluff CLJ, Wagner SN, Bruggen P, Baar J, Lotze MT, Storkus WJ (1998) Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by co-transfection of genes encoding the Th1-biasing cytokines IL-12 and IFN alfa. J Immunol Methods 160:1139-1147
10. Shimizu K, Fields RC, Giedlin M, Mule JJ (1999) Systemic adminstration of interleukin 2 enhances the therapeutic effficacy of dendritic cell-based tumor vaccine. Proc Natl Acad Sci USA 96:2268-2273
11. Chen S, Akbar SM, Tanimoto K, Ninomiya T, Iuchi H, Michitaka K, Horiike N, Onji M (2000) Absence of CD83(+)-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: relevance to hepatocarcinogenesis. Cancer Lett 148:49-57
12. Van-de-Velde AL, Berneman ZN, Van-Tendeloo VF (2008) Immunotherapy of hematological malignancies using dendritic cells. Bull Cancer 95:320-326
13. Draube A, Klein-González N, Mattheus S, Brillant C, Hellmich M, Engert A, von Bergwelt-Baildon M (2011) Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. LoS One 6:e18801
14. Alexandrescu DT, Ichim TE, Riordan NH, Marincola FM, Di-Nardo A, Kabigting FD, Dasanu CA (2010) Immunotherapy for melanoma: current status and perspectives. J Immunother 33:570-590
15. Mazzolini G, Murillo O, Atorrasagasti C, Dubrot J, Tirapu I, Rizzo M, Arina A, Alfaro C, Azpilicueta A, Berasain C, Perez-Gracia JL, Gonzales A, Melero I (2007) Immunotherapy and immunoescape in colorectal cancer. World J Gastroenterol 13:5822-5831
16. Dauer M, Schnurr M, Eigler A (2008) Dendritic cell-based cancer vaccination: quo vadis? Expert Rev Vaccines 7:1041-1053
17. Nencioni A, Grünebach F, Schmidt SM, Müller MR, Boy D, Patrone F, Ballestrero A, Brossart P (2008) The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 65:191-199
18. Vulink A, Radford KJ, Melief C, Hart DN (2008) Dendritic cells in cancer immunotherapy. Adv Cancer Res 99:363-407
19. Erreni M, Mantovani A, Allavena P (2011) Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron 4:141-154
20. Roxburgh C, McMillan D (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6:149-163
21. Roxburgh C, McMillan D (2012) The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 38(5):451-466. doi: 10.1016/j.ctrv.2011.09. 001, Epub 2011 Sep 25
22. database-online http://www.cancer.org/Cancer/ColonandRectumCancer/ DetailedGuide/colorectal-cancer-survival-rates. Last Medical Review: 05/24/2012; Last Revised: 01/17/2013
23. Palucka K, Banchereau J, Mellman I (2010) Designing vaccines based on biology of human dendritic cell subsets. Immunity 33:464-478
24. Nestle F, Banchereau J, Hart D (2001) Dendritic cells: on the move from bench to bedside. Nat Med 7:761-765
25. Figdor C, Jd V, Lesterhuis W, Melief C (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10:475-480
26. Dhodapkar MV, Krasovsky J, Steinman RM, Bhardwaj N (2000) Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J Clin Invest 105:9-14
27. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paragnik L, Kandemir A, Lee PP, Schuler G, Knop J, Enk AH (2001) A comparison of two types of dendritic cells as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93:243-251
28. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitro-derived dendritic cell vaccine. Cancer Res 61:6451-6458
29. Schuler-Thurnmer B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G (2002) Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195:1279-1288
30. Martin-Fontecha A, Sebastiani S, Höpken U, Uguccioni M, Lipp M, Lanzavecchia A, Sallusto F (2003) Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 198:615-621
31. Jefford M, Maraskovsky E, Cebon J, Davies ID (2001) The use of dendritic cells in cancer therapy. Lancet Oncol 2(6):343-353
32. Steinman RM, Dhodapkar M (2001) Active immunization against cancer with dendritic cells: the near future. Int J Cancer 94:459-473
33. Cerundolo V, Hermans I, Salio M (2004) Dendritic cells: a journey from laboratory to clinic. Nat Immunol 5:7-10
34. Cranmer L, Trevor K, Hersh E (2004) Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 53:275-306
35. Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L (2007) Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother 30:762-772
36. Mocellin S, Rossi C, Lise M, Nitti D (2004) Colorectal cancer vaccines: principles, results, and perspectives. Gastroenterology 127:1821-1837
37. Mosolits S, Ullenhag G, Mellstedt H (2005) Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol 16:847-862
38. Nagorsen D, Thiel E (2006) Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 12:3064-3069
39. Ridgway D (2003) The first 1000 dendritic cell vaccinees. Cancer Invest 21:873-886
40. Rosenberg S (2004) Development of effective immunotherapy for the treatment of patients with cancer. J Am Coll Surg 198:685-696
41. Rosenberg S, Yang J, Restifo N (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909-915
42. Lesterhuis WJ, De Vries IJ, Schreibelt G, Schuurhuis DH, Aarntzen EH, De Boer A, Scharenborg NM, Van De Rakt M, Hesselink EJ, Figdor CG, Adema GJ, Punt CJ (2010) Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res 30:5091-5097
43. Okuno K, Sugiura F, Itoh K, Yoshida K, Tsunoda T, Nakamura Y (2012) Recent advances in active specific cancer vaccine treatment for colorectal cancer. Curr Pharm Biotechnol(Feb 14), PMID: 22339221
44. Sakakibara M, Kanto T, Hayakawa M, Kuroda S, Miyatake H, Itose I, Miyazaki M, Kakita N, Higashitani K, Matsubara T, Hiramatsu N, Kasahara A, Takehara T, Hayashi N (2011) Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide. Cancer Immunol Immunother 60:1565-1575
45. Zhou Q, Peng R, Wu X, Xia Q, Hou J, Ding Y, Zhou Q, Zhang X, Pang Z, Wan D, Zeng Y, Zhang X (2010) The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. J Transl Med 8:13
46. Nagaraj S, Gabrilovich DI (2012) Regulation of suppressive function of myeloid-derived suppressor cells by CD4(+) T cells. Semin Cancer Biol 22(4):282-288. doi: 10.1016/j.semcancer.2012.01.010, Epub 2012 Jan 31
47. Erdman S, Sohn J, Rao V, Nambiar P, Ge Z, Fox J, Schauer D (2005) CD4∈+∈CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res 65:3998-4004
48. Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant J, Ménégaux F, Rosenzwajg M, Lemoine F, Klatzmann D, Taieb J (2009) Identification of CD8∈+∈CD25∈+∈Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 58:520-529
49. Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C (2007) Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med 29:62
50. Gilboa E (2001) The risk of autoimmunity asssociated with tumor immunotherapy. Nat Immunol 2:789-792